GlassScriptPhysician profile
Harvey Brilliant
NPI 1427143833
$2,928.41
in general payments reported to CMS, 2019-2025
16 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,584 · 2020: $468 · 2021: $471 · 2023: $144 · 2024: $148 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,105.96 | 2019-2021 | |
| Baxter Healthcare | $490.00 | 2021-2025 | Tisseel |
| Therapeuticsmd, INC. | $320.59 | 2019-2021 | |
| Allergan, INC. | $235.48 | 2019-2020 | |
| Lupin INC. | $199.78 | 2019-2020 | |
| Pfizer INC. | $137.04 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $123.77 | 2019-2020 | |
| Ethicon US, LLC | $111.47 | 2019 | |
| Vertical Pharmaceuticals, LLC | $41.37 | 2019 | |
| Myovant Sciences INC. | $37.60 | 2021 | |
| Duchesnay USA Incorporated | $27.04 | 2019 | |
| Mayne Pharma Commercial LLC | $26.69 | 2021 | |
| Astellas Pharma US INC | $19.31 | 2019 | |
| Assertio Therapeutics, INC. | $19.25 | 2019 | |
| Axonics, INC. | $17.24 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $15.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harvey Brilliant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.